Efficacy of Fluoroquinolone/Probiotic Combination Therapy for Recurrent Urinary Tract Infection in Children: A Retrospective Analysis

Ramiro J. Madden-Fuentes, Mehreen Arshad, Sherry S. Ross, Patrick C. Seed*

*Corresponding author for this work

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose Children with normal urinary tract anatomy and function and highly recurrent urinary tract infection (rUTI) may have a lack of alternatives when antibiotic prophylaxis and "watchful waiting" approaches fail. This retrospective review reports the outcomes in children who received a fluoroquinolone/probiotic combination in an attempt to quantify a reduction in rUTI that was perceived by both clinicians and patients' families. Methods Data from all children with rUTIs previously managed with a fluoroquinolone/probiotic combination at the Pediatric Infectious Diseases Clinic at Duke University Medical Center (Durham, North Carolina) were identified and analyzed. Finding Data from 10 children were eligible for inclusion. Compared with before therapy initiation, total UTI episodes were significantly fewer after therapy initiation (57 vs 4; P = 0.0001). Seven (70%) were free of rUTIs during the follow-up period. Of the 8 patients with known compliance, 7 (88%) were free of rUTIs. Implications Given the chronic nature of these patients' symptoms, the significant decrease in UTI after the initiation of therapy, and the increase in the interval without an infection and/or its symptoms, this treatment regimen has the potential to improve overall quality of life, decrease antibiotic courses, and decrease health care costs in children with rUTI. These results will be validated with a larger cohort of patients in a prospective, randomized trial.

Original languageEnglish (US)
Article number2628
Pages (from-to)2143-2147
Number of pages5
JournalClinical Therapeutics
Volume37
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Fluoroquinolones
Probiotics
Urinary Tract Infections
Watchful Waiting
Therapeutics
Antibiotic Prophylaxis
Urinary Tract
Health Care Costs
Compliance
Communicable Diseases
Anatomy
Quality of Life
Pediatrics
Anti-Bacterial Agents
Infection

Keywords

  • children
  • fluoroquinolone
  • probiotics
  • recurrent urinary tract infections

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{920e7b27bb70429d9f0fb08b4a3cb488,
title = "Efficacy of Fluoroquinolone/Probiotic Combination Therapy for Recurrent Urinary Tract Infection in Children: A Retrospective Analysis",
abstract = "Purpose Children with normal urinary tract anatomy and function and highly recurrent urinary tract infection (rUTI) may have a lack of alternatives when antibiotic prophylaxis and {"}watchful waiting{"} approaches fail. This retrospective review reports the outcomes in children who received a fluoroquinolone/probiotic combination in an attempt to quantify a reduction in rUTI that was perceived by both clinicians and patients' families. Methods Data from all children with rUTIs previously managed with a fluoroquinolone/probiotic combination at the Pediatric Infectious Diseases Clinic at Duke University Medical Center (Durham, North Carolina) were identified and analyzed. Finding Data from 10 children were eligible for inclusion. Compared with before therapy initiation, total UTI episodes were significantly fewer after therapy initiation (57 vs 4; P = 0.0001). Seven (70{\%}) were free of rUTIs during the follow-up period. Of the 8 patients with known compliance, 7 (88{\%}) were free of rUTIs. Implications Given the chronic nature of these patients' symptoms, the significant decrease in UTI after the initiation of therapy, and the increase in the interval without an infection and/or its symptoms, this treatment regimen has the potential to improve overall quality of life, decrease antibiotic courses, and decrease health care costs in children with rUTI. These results will be validated with a larger cohort of patients in a prospective, randomized trial.",
keywords = "children, fluoroquinolone, probiotics, recurrent urinary tract infections",
author = "Madden-Fuentes, {Ramiro J.} and Mehreen Arshad and Ross, {Sherry S.} and Seed, {Patrick C.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.clinthera.2015.06.018",
language = "English (US)",
volume = "37",
pages = "2143--2147",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "9",

}

Efficacy of Fluoroquinolone/Probiotic Combination Therapy for Recurrent Urinary Tract Infection in Children : A Retrospective Analysis. / Madden-Fuentes, Ramiro J.; Arshad, Mehreen; Ross, Sherry S.; Seed, Patrick C.

In: Clinical Therapeutics, Vol. 37, No. 9, 2628, 01.09.2015, p. 2143-2147.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of Fluoroquinolone/Probiotic Combination Therapy for Recurrent Urinary Tract Infection in Children

T2 - A Retrospective Analysis

AU - Madden-Fuentes, Ramiro J.

AU - Arshad, Mehreen

AU - Ross, Sherry S.

AU - Seed, Patrick C.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Purpose Children with normal urinary tract anatomy and function and highly recurrent urinary tract infection (rUTI) may have a lack of alternatives when antibiotic prophylaxis and "watchful waiting" approaches fail. This retrospective review reports the outcomes in children who received a fluoroquinolone/probiotic combination in an attempt to quantify a reduction in rUTI that was perceived by both clinicians and patients' families. Methods Data from all children with rUTIs previously managed with a fluoroquinolone/probiotic combination at the Pediatric Infectious Diseases Clinic at Duke University Medical Center (Durham, North Carolina) were identified and analyzed. Finding Data from 10 children were eligible for inclusion. Compared with before therapy initiation, total UTI episodes were significantly fewer after therapy initiation (57 vs 4; P = 0.0001). Seven (70%) were free of rUTIs during the follow-up period. Of the 8 patients with known compliance, 7 (88%) were free of rUTIs. Implications Given the chronic nature of these patients' symptoms, the significant decrease in UTI after the initiation of therapy, and the increase in the interval without an infection and/or its symptoms, this treatment regimen has the potential to improve overall quality of life, decrease antibiotic courses, and decrease health care costs in children with rUTI. These results will be validated with a larger cohort of patients in a prospective, randomized trial.

AB - Purpose Children with normal urinary tract anatomy and function and highly recurrent urinary tract infection (rUTI) may have a lack of alternatives when antibiotic prophylaxis and "watchful waiting" approaches fail. This retrospective review reports the outcomes in children who received a fluoroquinolone/probiotic combination in an attempt to quantify a reduction in rUTI that was perceived by both clinicians and patients' families. Methods Data from all children with rUTIs previously managed with a fluoroquinolone/probiotic combination at the Pediatric Infectious Diseases Clinic at Duke University Medical Center (Durham, North Carolina) were identified and analyzed. Finding Data from 10 children were eligible for inclusion. Compared with before therapy initiation, total UTI episodes were significantly fewer after therapy initiation (57 vs 4; P = 0.0001). Seven (70%) were free of rUTIs during the follow-up period. Of the 8 patients with known compliance, 7 (88%) were free of rUTIs. Implications Given the chronic nature of these patients' symptoms, the significant decrease in UTI after the initiation of therapy, and the increase in the interval without an infection and/or its symptoms, this treatment regimen has the potential to improve overall quality of life, decrease antibiotic courses, and decrease health care costs in children with rUTI. These results will be validated with a larger cohort of patients in a prospective, randomized trial.

KW - children

KW - fluoroquinolone

KW - probiotics

KW - recurrent urinary tract infections

UR - http://www.scopus.com/inward/record.url?scp=84941261266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941261266&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2015.06.018

DO - 10.1016/j.clinthera.2015.06.018

M3 - Article

C2 - 26233470

AN - SCOPUS:84941261266

VL - 37

SP - 2143

EP - 2147

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 9

M1 - 2628

ER -